Invasive pneumococcal disease: From a tertiary care hospital in the post-vaccine era

Tanır Basaranoglu S., Karadag Oncel E., AYKAÇ K., ÖZSÜREKCİ Y., CENGİZ A. B., KARA A., ...More

Human Vaccines and Immunotherapeutics, vol.13, no.4, pp.962-964, 2017 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 4
  • Publication Date: 2017
  • Doi Number: 10.1080/21645515.2016.1256519
  • Journal Name: Human Vaccines and Immunotherapeutics
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.962-964
  • Keywords: antibiotic resistance, breakthrough infection, invasive pneumococcus disease, Streptococcus pneumoniae, surveillance, vaccination, vaccine failure
  • Dokuz Eylül University Affiliated: No


A breakthrough infection occurring with 13-valent pneumococcal conjugate vaccine (PCV13) in Turkey are previously described. A breakthrough infection is defined as IPD in a child who had received ≥ 1 PCV-7 or PCV-13 and for which the pneumococcal isolate was a vaccine serotype. During one year period, among 6 patients with invasive pneumococcal infection, 2 patients were considered to have a vaccine failure with serotype 19F. Antibiotic resistance results were remarkable; macrolide resistance were observed in all strains except one, and high and intermediate penicillin resistance were determined in 2 strains.